Medigene AG - Asset Resilience Ratio

Latest as of December 2023: 25.22%

Medigene AG (MDG1) has an Asset Resilience Ratio of 25.22% as of December 2023. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. Read total liabilities of Medigene AG for a breakdown of total debt and financial obligations.

Liquid Assets

€8.00 Million
≈ $9.35 Million USD Cash + Short-term Investments

Total Assets

€31.72 Million
≈ $37.08 Million USD All company assets

Resilience Assessment

Very High
Financial Resilience Level

Asset Resilience Ratio Trend (2012–2023)

This chart shows how Medigene AG's Asset Resilience Ratio has changed over time. See what is Medigene AG's book value for net asset value and shareholders' equity analysis.

Liquid Assets Composition Over Time

This chart breaks down Medigene AG's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For market capitalisation and broader financial context, see how much is Medigene AG worth.

Current Liquid Assets Breakdown

Component Amount % of Total Assets
Cash & Equivalents €0.00 0%
Short-term Investments €8.00 Million 25.22%
Total Liquid Assets €8.00 Million 25.22%

Asset Resilience Insights

  • Very High Liquidity: Medigene AG maintains exceptional liquid asset reserves at 25.22% of total assets.
  • This level provides strong protection against economic uncertainties but may indicate potential for more aggressive growth investments.
  • The company has significant short-term investments, indicating active treasury management.

Medigene AG Industry Peers by Asset Resilience Ratio

Compare Medigene AG's asset resilience ratio with other companies in the same industry.

Company Industry Asset Resilience Ratio
Argen-X
F:1AE
Biotechnology 25.67%
Tubize-Fin
BR:TUB
Biotechnology 0.05%
BrightGene Bio Medical Technology C
SHG:688166
Biotechnology 1.00%
Dashenlin Pharm Grp Co Ltd
SHG:603233
Biotechnology 0.02%
Staidson Beijing Biopharma
SHE:300204
Biotechnology 7.93%
Tibet Cheezheng Tibetan Medicine Co Ltd
SHE:002287
Biotechnology 41.25%
Ardelyx Inc
NASDAQ:ARDX
Biotechnology 41.14%
Xiangxue Pharmaceutical
SHE:300147
Biotechnology 0.05%

Annual Asset Resilience Ratio for Medigene AG (2012–2023)

The table below shows the annual Asset Resilience Ratio data for Medigene AG.

Year Asset Resilience Ratio (%) Liquid Assets Total Assets Change
2023-12-31 25.22% €8.00 Million
≈ $9.35 Million
€31.72 Million
≈ $37.08 Million
-39.07pp
2022-12-31 64.29% €33.22 Million
≈ $38.84 Million
€51.68 Million
≈ $60.42 Million
+26.60pp
2021-12-31 37.69% €22.42 Million
≈ $26.21 Million
€59.47 Million
≈ $69.53 Million
-2.48pp
2020-12-31 40.18% €30.03 Million
≈ $35.11 Million
€74.75 Million
≈ $87.39 Million
-9.89pp
2019-12-31 50.07% €54.68 Million
≈ $63.93 Million
€109.22 Million
≈ $127.68 Million
+10.40pp
2018-12-31 39.67% €51.41 Million
≈ $60.10 Million
€129.59 Million
≈ $151.50 Million
-6.54pp
2017-12-31 46.21% €51.72 Million
≈ $60.47 Million
€111.94 Million
≈ $130.87 Million
-0.90pp
2016-12-31 47.11% €52.63 Million
≈ $61.53 Million
€111.72 Million
≈ $130.61 Million
+13.64pp
2015-12-31 33.47% €38.00 Million
≈ $44.43 Million
€113.53 Million
≈ $132.73 Million
+33.22pp
2014-12-31 0.25% €180.00K
≈ $210.44K
€71.28 Million
≈ $83.34 Million
-0.04pp
2013-12-31 0.29% €154.00K
≈ $180.04K
€52.66 Million
≈ $61.56 Million
-0.30pp
2012-12-31 0.59% €362.00K
≈ $423.22K
€61.26 Million
≈ $71.61 Million
--
pp = percentage points

About Medigene AG

XETRA:MDG1 Germany Biotechnology
Market Cap
$2.30 Million
€1.97 Million EUR
Market Cap Rank
#29703 Global
#2605 in Germany
Share Price
€0.13
Change (1 day)
+0.00%
52-Week Range
€0.13 - €0.13
All Time High
€36.05
About

Medigene AG, a biotechnology company, focuses on the discovery and development of T-cell therapies for the treatment of cancer. The company's end-to-end platform enables the development of T cell receptor engineered T cell (TCR-T) therapies for multiple tumor indications. Its lead product includes MDG1015, a TCR-T therapy product to treat multiple solid tumor indications. The company also develop… Read more